Insider Selling: Aquestive Therapeutics (NASDAQ:AQST) Insider Sells $124,324.38 in Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) insider Peter Boyd sold 29,814 shares of Aquestive Therapeutics stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total transaction of $124,324.38. Following the sale, the insider owned 338,509 shares of the company’s stock, valued at $1,411,582.53. The trade was a 8.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Aquestive Therapeutics Price Performance

Shares of AQST opened at $4.02 on Friday. The company’s fifty day moving average price is $3.99 and its 200-day moving average price is $5.20. Aquestive Therapeutics, Inc. has a 1-year low of $2.12 and a 1-year high of $7.55. The firm has a market capitalization of $490.60 million, a PE ratio of -5.15 and a beta of 1.61.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Wednesday, March 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). The company had revenue of $13.02 million during the quarter, compared to the consensus estimate of $13.28 million. As a group, research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Lake Street Capital set a $6.00 target price on Aquestive Therapeutics in a report on Tuesday, February 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Wednesday, January 21st. Finally, Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $8.80.

Institutional Investors Weigh In On Aquestive Therapeutics

Several hedge funds have recently added to or reduced their stakes in AQST. Commonwealth Equity Services LLC purchased a new position in shares of Aquestive Therapeutics during the 3rd quarter valued at about $5,918,000. Pale Fire Capital SE lifted its holdings in shares of Aquestive Therapeutics by 25.5% in the 2nd quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company’s stock valued at $5,549,000 after buying an additional 340,767 shares during the period. Aberdeen Group plc purchased a new stake in shares of Aquestive Therapeutics in the third quarter worth about $3,494,000. Sio Capital Management LLC boosted its stake in shares of Aquestive Therapeutics by 141.9% in the second quarter. Sio Capital Management LLC now owns 947,489 shares of the company’s stock worth $3,136,000 after buying an additional 555,860 shares during the last quarter. Finally, Diametric Capital LP acquired a new stake in Aquestive Therapeutics during the second quarter worth about $547,000. 32.45% of the stock is owned by hedge funds and other institutional investors.

Aquestive Therapeutics News Summary

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: HC Wainwright issued a more favorable near‑term earnings outlook and raised some FY estimates, offering modest analytical support if operational/regulatory progress continues. HC Wainwright Estimates
• Neutral Sentiment: Coverage pieces (market commentary) explain recent volatility and provide context for regulatory risk tied to Anaphylm; these explain price moves but do not change fundamentals immediately. AAII: Why AQST Is Down
• Neutral Sentiment: Short‑interest figures circulating this week show anomalous zero/NaN values (likely reporting error) and should not be used to support a short‑squeeze thesis until official confirmations are posted. (No authoritative link provided.)
• Negative Sentiment: Multiple law firms have filed or advertised class actions for purchasers between June 16, 2025 and Jan 8, 2026; several solicitations for lead‑plaintiff roles raise the prospect of material litigation costs, management distraction, and downside risk to the stock. Rosen Law Firm Notice
• Negative Sentiment: Additional class‑action notices from other firms (Pomerantz, Faruqi, Bernstein, Portnoy) amplify the legal narrative and extend the timeline of investor uncertainty. Pomerantz Alert
• Negative Sentiment: Insider selling: a disclosed sale (15,741 shares by Sherry Korczynski and other senior officer transactions) at roughly $4.17 reduces insider holdings and is often interpreted negatively by the market. InsiderTrades: Insider Sale
• Negative Sentiment: A PR Newswire item highlights an allegation tied to an analyst’s large price‑target cut (Cantor), linking that cut to a sharp one‑day selloff; this adds to reputational/regulatory narrative around prior communications and approval risk for Anaphylm. PR Newswire: Analyst Lawsuit

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.